Neuro-oncology · 2026
Efficacy and safety of aumolertinib/icotinib combination therapy for naive EGFR-mutant non-small-cell lung cancer patients with brain metastases: A phase I/II study.
СтатьяКлиническое исследование I фазыКлиническое исследование II фазыНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Min, Chen Caini, Gong Youling, Tian Tian, Li Yanying, Fan Hua, Zhang Lizhi, Deng Wen, Liu Yongmei, Peng Feng, Yu Yang, Xiu Weigang, Wang Yongsheng, Zou Bingwen, Zhang Xuanwei, Zhong Liqiang, Liu Tianqiong, Wang Xianfeng, Xu Yong, Zhou Lin, Lu You, Huang Meijuan
Аннотация
BACKGROUND: The benefits of offering first- and third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for treatment-naive EGFR-mutant non-small-cell lung cancer patients (NSCLC) with brain metastases (BMs) are unknown. This trial aims to assess the feasibility, safety, and efficacy of icotinib plus aumolertinib in these patients.
METHODS: The phase I/II trial (ChiCTR2100044216) employed a 3 + 3 dose-escalation and dose-expansion design targeting EGFR-mutant NSCLC patients with baseline measurable BMs. Primary endpoints were the recommended phase II dose (RP2D) and feasibility. Major secondary endpoints included median overall survival (OS), systemic and intracranial progression-free survival (PFS and iPFS), objective response rate (ORR and iORR), and safety profile.
RESULTS: Twenty-four eligible patients were evaluated with a median follow-up of 41.4 months. The RP2D was 125 mg icotinib 3 times daily plus 110 mg aumolertinib once daily. Median PFS was 21.1 months (95% CI 14.6-27.6 months) and median OS was 40.8 months (95% CI 29.1-52.5). ORR was 95.8% and the disease control rate (DCR) was 100%. Median iPFS was 22.5 months (95% CI 17.5-27.6 months) with iORR of 91.7% and intracranial DCR of 100%. For safety profile, grade ≥3 treatment-related adverse events (TRAEs) occurred in 37.5% of patients. The most common any-grade TRAEs were increases in alanine aminotransferase, aspartate aminotransferase, creatine kinase, and rash.
CONCLUSIONS: The combination of aumolertinib and icotinib shows encouraging efficacy and a tolerable safety profile in patients with EGFR-mutant NSCLC and BMs, supporting its potential as a therapeutic option warranting further investigation.
METHODS: The phase I/II trial (ChiCTR2100044216) employed a 3 + 3 dose-escalation and dose-expansion design targeting EGFR-mutant NSCLC patients with baseline measurable BMs. Primary endpoints were the recommended phase II dose (RP2D) and feasibility. Major secondary endpoints included median overall survival (OS), systemic and intracranial progression-free survival (PFS and iPFS), objective response rate (ORR and iORR), and safety profile.
RESULTS: Twenty-four eligible patients were evaluated with a median follow-up of 41.4 months. The RP2D was 125 mg icotinib 3 times daily plus 110 mg aumolertinib once daily. Median PFS was 21.1 months (95% CI 14.6-27.6 months) and median OS was 40.8 months (95% CI 29.1-52.5). ORR was 95.8% and the disease control rate (DCR) was 100%. Median iPFS was 22.5 months (95% CI 17.5-27.6 months) with iORR of 91.7% and intracranial DCR of 100%. For safety profile, grade ≥3 treatment-related adverse events (TRAEs) occurred in 37.5% of patients. The most common any-grade TRAEs were increases in alanine aminotransferase, aspartate aminotransferase, creatine kinase, and rash.
CONCLUSIONS: The combination of aumolertinib and icotinib shows encouraging efficacy and a tolerable safety profile in patients with EGFR-mutant NSCLC and BMs, supporting its potential as a therapeutic option warranting further investigation.